Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment

Fig. 3

Correlation of HER2 RNAscope scores and pCR rates among HER2 IHC/FISH categories in the 270 patients with HER2-positive BCs receiving NCTT. Dotplots denoting the disctribution of HER2 RNAscope scores (A) and HER2 RNA-seq TPM (B) among the two HER2-positive BC groups. Barplot and dotplot denoting the pCR rates (C) and HER2 RNAscope scores (D), respectively, among each HER2-positive IHC/FISH category. Barplots denoting the pCR rates among HER2-positive IHC/FISH categories stratified by HER2 RNAscope scores (1–2, 3, 4, and 5) (E) or (1–4 and 5) (F). G Dotplot showing HER2 RNAscope scores in patients with or without pCR among the HER2-positive IHC/FISH categories. Barplot and dotplot denoting the pCR rates (H) and HER2 RNAscope scores (I), respectively, among cases with IHC 2 + or IHC 3 + stratified by FISH result. Mean is shown in red line. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us